Literature DB >> 24078408

Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population.

Jinshan He, Jingcheng Wang, Daxin Wang, Shanhe Dai, Tangyun Yv, Pengtao Chen, Renshi Ma, Chunyv Diao, Guohua Lv.   

Abstract

Osteosarcoma (OS) is the most common malignant primary bone tumor in the world. The cytotoxic T-lymphocyte antigen-4 gene (CTLA-4) is an important candidate gene for influencing the development of OS. This study aimed to investigate the potential association of CTLA-4 genetic polymorphisms with OS risk in Chinese Han population. A total of 415 OS patients and 431 healthy controls were enrolled in this study. The created restriction site-polymerase chain reaction (CRS-PCR) and DNA sequencing methods were used to detect the genotyping of CTLA-4 c.75G[C and c.326G[A genetic polymorphisms. We observed that the genotypes/alleles of c.75G[C and c.326G[A genetic polymorphisms were statistically associated with the increased risk of OS (for c.75G[C, CC versus (vs.) GG: OR 1.72, 95% CI 1.09–2.74; C vs. G: OR 1.30, 95% CI 1.06–1.60; for c.326G[A, AA vs. GG: OR 2.12, 95% CI 1.31–3.42; A vs. G: OR 1.31, 95% CI 1.07–1.61). The allele-C/genotype-CC of c.75G[C and allele-A/genotype-AA of c.326G[A may contribute to OS susceptibility. These data indicate that CTLA-4 genetic polymorphisms are potentially related to OS risk in Chinese Han population, and might be used as molecular markers for evaluating the risk of OS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24078408     DOI: 10.1007/s12020-013-0050-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  29 in total

1.  Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma.

Authors:  Yang Liu; Zhimin He; Dapeng Feng; Guodong Shi; Rui Gao; Xiaodong Wu; Weiguo Song; Wen Yuan
Journal:  DNA Cell Biol       Date:  2011-05-25       Impact factor: 3.311

2.  Modification of enzymatically amplified DNA for the detection of point mutations.

Authors:  A Haliassos; J C Chomel; L Tesson; M Baudis; J Kruh; J C Kaplan; A Kitzis
Journal:  Nucleic Acids Res       Date:  1989-05-11       Impact factor: 16.971

3.  Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma.

Authors:  Wen Wang; Jian Wang; Haihan Song; Jie Liu; Bao Song; Xuecheng Cao
Journal:  Genet Test Mol Biomarkers       Date:  2011-03-31

Review 4.  Osteosarcoma: a multidisciplinary approach to diagnosis and treatment.

Authors:  James C Wittig; Jacob Bickels; Dennis Priebat; James Jelinek; Kristen Kellar-Graney; Barr Shmookler; Martin M Malawer
Journal:  Am Fam Physician       Date:  2002-03-15       Impact factor: 3.292

5.  CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction.

Authors:  Elisabetta Contardi; Giulio L Palmisano; Pier Luigi Tazzari; Alberto M Martelli; Federica Falà; Marina Fabbi; Tomohiro Kato; Enrico Lucarelli; Davide Donati; Letizia Polito; Andrea Bolognesi; Francesca Ricci; Sandra Salvi; Vittoria Gargaglione; Stefano Mantero; Marco Alberghini; Giovanni Battista Ferrara; Maria Pia Pistillo
Journal:  Int J Cancer       Date:  2005-11-20       Impact factor: 7.396

Review 6.  CTLA-4: new insights into its biological function and use in tumor immunotherapy.

Authors:  Jackson G Egen; Michael S Kuhns; James P Allison
Journal:  Nat Immunol       Date:  2002-07       Impact factor: 25.606

7.  Bone cancers.

Authors:  H D Dorfman; B Czerniak
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

8.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

9.  Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.

Authors:  Daniela Caronia; Ana Patiño-Garcia; Antonio Peréz-Martínez; Guillermo Pita; Leticia Tais Moreno; Marta Zalacain-Díez; Blanca Molina; Isabel Colmenero; Luis Sierrasesúmaga; Javier Benítez; Anna Gonzalez-Neira
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

10.  Lysyl oxidase polymorphisms and susceptibility to osteosarcoma.

Authors:  Yang Liu; Bitao Lv; Zhimin He; Yujia Zhou; Carrie Han; Guodong Shi; Rui Gao; Ce Wang; Lili Yang; Haihan Song; Wen Yuan
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.752

View more
  9 in total

1.  Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.

Authors:  Yongjian Sun; Yi Wu; Weicheng Li; Zhen Kong; Xiaoming Zou
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

2.  Single nucleotide polymorphisms in VEGF gene are associated with an increased risk of osteosarcoma.

Authors:  Zhang Tie; Rui Bai; Zhongwen Zhai; Gang Zhang; Hong Zhang; Zhenqun Zhao; Deshan Zhou; Wanlin Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 3.  Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.

Authors:  D Matthew Gianferante; Lisa Mirabello; Sharon A Savage
Journal:  Nat Rev Endocrinol       Date:  2017-03-24       Impact factor: 43.330

Review 4.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

5.  CD 152 gene polymorphisms and risk of osteosarcoma in Chinese population.

Authors:  Zhengqi Chang; Ruoxian Song; Songfeng Xu; Ming Xu; Xiuchun Yu
Journal:  Tumour Biol       Date:  2014-04-12

6.  Investigation on the role of VEGF gene polymorphisms in the risk of osteosarcoma.

Authors:  Zhao Li-Lian; Wang Lin; Shi Lei; Zhang Yao-Nan
Journal:  Pak J Med Sci       Date:  2015 Mar-Apr       Impact factor: 1.088

Review 7.  Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma.

Authors:  Vafa Meftahpour; Ali Aghebati-Maleki; Ali Fotouhi; Elham Safarzadeh; Leili Aghebati-Maleki
Journal:  EXCLI J       Date:  2022-01-12       Impact factor: 4.068

Review 8.  T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.

Authors:  Zhan Wang; Binghao Li; Yingqing Ren; Zhaoming Ye
Journal:  Front Immunol       Date:  2016-09-14       Impact factor: 7.561

9.  Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis.

Authors:  Clara Benna; Andrea Simioni; Sandro Pasquali; Davide De Boni; Senthilkumar Rajendran; Giovanna Spiro; Chiara Colombo; Calogero Virgone; Steven G DuBois; Alessandro Gronchi; Carlo Riccardo Rossi; Simone Mocellin
Journal:  Oncotarget       Date:  2018-04-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.